Antitumor effects of interferon-alpha on cell growth and metastasis in human nasopharyngeal carcinoma

Current Cancer Drug Targets

Volumn 12, Issue 5, 2012, Pages 561-570

  Liu, X ^a   Lu, J ^a   He, M L ^b,c   Li, Z ^d   Zhang, B ^a   Zhou, L H ^e   Li, Q ^a   Li, G ^a   Wang, L ^a   Tian, W D ^a   Peng, Y ^f   Li, X P ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c Prince of Wales Hospital   (Hong Kong)

^d SHANXI NORMAL UNIVERSITY   (China)

^e 150 central hospital of PLA   (China)

^f SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cell growth; Cytokine; Immunotherapy; Interferon a1b; Metastasis; Nasopharyngeal carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; CYCLIN DEPENDENT KINASE 6; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN RECOMBINANT INTERFERON ALPHA1B; INTERLEUKIN 12; PARVOVIRUS VECTOR; PROTEIN P16; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL PARAMETERS; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL DEATH; CELL SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; EXPERIMENTAL NEOPLASM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRATUMORAL MICROVESSEL DENSITY; MALE; METASTASIS INHIBITION; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; VIRUS RECOMBINANT;

EID: 84861728745     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912800673293     Document Type: Article

References (50)

1. Lo, K. W.; To, K. F.; Huang, D. P. Focus on nasopharyngeal carcinoma. Cancer Cell. 2004, 5, 423-428.
2. Yoshizaki, T. Promotion of metastasis in nasopharyngeal carcinoma by Epstein-Barr virus latent membrane protein-1. Histol. Histopathol. 2002, 17, 845-850.
3. Haddad, R. I.; Shin, D. M. Recent advances in head and neck cancer. N. Engl. J. Med. 2008, 359, 1143-1154.
4. Chua, D. T.; Sham, J. S.; Leung, L. H.; Au, G. K. Re-irradiation of nasopharyngeal carcinoma with intensity-modulated radiotherapy. Radiother. Oncol. 2005, 77, 290-294.
5. Wei, K. R.; Yu, Y. L.; Yang, Y. Y.; Ji, M. F.; Yu, B. H.; Liang, Z. H.; Reng, X. Epidemiological trends of nasopharyngeal carcinoma in China. Asian. Pac. J. Cancer Prev. 2010, 11, 29-32.
6. Lee, C. C.; Huang, T. T.; Lee, M. S.; Hsiao, S. H.; Lin, H. Y.; Su, Y. C.; Hsu, F. C.; Hung, S. K. Clinical application of tumor volume in advanced nasopharyngeal carcinoma to predict outcome. Radiat. Oncol. 2010, 11, 20.
7. Hadden, J. W. Immunodeficiency and cancer: prospects for correction. Int. Immunopharmacol. 2003, 3, 1061-1071.
8. Zhang, L.; Conejo-Garcia, J. R.; Katsaros, D.; Gimotty, P. A.; Massobrio, M.; Regnani, G.; Makrigiannakis, A.; Gray, H.; Schlienger, K.; Liebman, M. N.; Rubin, S. C.; Coukos, G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003, 348, 203-213.
9. Haanen, J. B.; Baars, A.; Gomez, R.; Weder, P.; Smits, M.; de Gruijl, T. D.; von Blomberg, B. M.; Bloemena, E.; Scheper, R. J., van Ham, S. M.; Pinedo, H. M.; van den Eertwegh, A. J. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol. Immunother. 2006, 55, 451-458.
10. Badoual, C.; Hans, S.; Rodriguez, J.; Peyrard, S.; Klein, C.; Agueznay, Nel. H.; Mosseri, V.; Laccourreye, O.; Bruneval, P.; Fridman, W. H.; Brasnu, D. F.; Tartour, E. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin. Cancer Res. 2006, 12, 465-472.
11. Yip, W. K.; Abdullah, M. A.; Yusoff, S. M.; Seow, H. F. Increase in tumour-infiltrating lymphocytes with regulatory T cell immunophenotypes and reduced zeta-chain expression in nasopharyngeal carcinoma patients. Clin. Exp. Immunol. 2009, 155, 412-422.
12. Albers, A. E.; Strauss, L.; Liao, T.; Hoffmann, T. K.; Kaufmann, A. M. T cell-tumor interaction directs the development of immunotherapies in head and neck cancer. Clin. Dev. Immunol. 2010, 2010, 236378.
13. Rapidis, A. D.; Wolf, G. T. Immunotherapy of head and neck cancer: current and future considerations. J Oncol. 2009, 2009, 346345.
14. Pestka, S. The interferons: 50 years after their discovery, there is much more to learn. J. Biol. Chem. 2007, 282, 20047-20051.
15. Dunn, G. P.; Koebel, C. M.; Schreiber, R. D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 2006, 6, 836-848.
16. Kirkwood, J. Cancer immunotherapy: the interferon-alpha experience. Semin. Oncol. 2002, 29, 18-26.
17. Diamond, M. S.; Kinder, M.; Matsushita, H.; Mashayekhi, M.; Dunn, G. P.; Archambault, J. M.; Lee, H.; Arthur, C. D.; White, J. M.; Kalinke, U.; Murphy, K. M.; Schreiber, R. D. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 2011, 208, 1989-2003.
18. Arnaud, P. The interferons: pharmacology, mechanism of action, tolerance and side effects. Rev. Med. Interne. 2002, 23 Suppl 4, 449s-458s.
19. Håkansson, A.; Gustafsson, B.; Krysander, L.; Håkansson, L. Effect of IFN-alpha on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma. J. Interferon. Cytokine. Res. 1998, 18, 33-39.
20. Liu, T.; Ding, Y.; Xie, W.; Li, Z.; Bai, X.; Li, X.; Fang, W.; Ren, C.; Wang, S.; Hoffman, R. M.; Yao, K. An imageable metastatic treatment model of nasopharyngeal carcinoma. Clin. Cancer Res. 2007, 13, 3960-3967.
21. Li, X. P.; Li, C. Y.; Li, X.; Ding, Y.; Chan, L. L.; Yang, P. H.; Li, G.; Liu, X.; Lin, J. S.; Wang, J.; He, M.; Kung, H. F.; Lin, M. C.; Peng, Y. Inhibition of human nasopharyngeal carcinoma growth and metastasis in mice by adenovirus-associated virus-mediated expression of human endostatin. Mol. Cancer Ther. 2006, 5, 1290-1298.
22. Li, Z.; Yao, H.; Ma, Y.; Dong, Q.; Chen, Y.; Peng, Y.; Zheng, B. J.; Huang, J. D.; Chan, C. Y.; Lin, M. C.; Sung, J. J.; Yuen, K. Y.; Kung, H. F.; He, M. L. Inhibition of HBV gene expression and replication by stably expressed interferon-alpha1 via adenoassociated viral vectors. J. Gene. Med. 2008, 10, 619-627.
23. Auricchio, A.; Hildinger, M.; O'Connor, E.; Gao, G. P.; Wilson, J. M. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum. Gene. Ther. 2001, 12, 71-76.
24. Su, Y.; Cheng, X.; Tan, Y.; Hu, Y.; Zhou, Y.; Liu, J.; Xu, Y.; Xie, Y.; Wang, C.; Gao, Y.; Wang, J.; Cheng, T.; Yang, C.; Xiong, D.; Miao, H. Synthesis of a dual functional anti-MDR tumor agent PH II-7 with elucidations of anti-tumor effects and mechanisms. PloS One 2012, 7, e32782.
25. Liu, W.; Swetzig, W. M.; Medisetty, R.; Das, G. M. Estrogenmediated upregulation of Noxa is associated with cell cycle progression in estrogen receptor-positive breast cancer cells. PLoS One 2011, 6, e29466.
26. Tomayko, M. M.; Reynolds, C. P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 1989, 24, 148-154.
27. Lu, J.; He, M. L.; Wang, L.; Chen, Y.; Liu, X.; Dong, Q.; Chen, Y. C.; Peng, Y.; Yao, K. T.; Kung, H. F.; Li, X. P. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res. 2011, 71, 225-233.
28. Sundaram, P.; Hultine, S.; Smith, L. M.; Dews, M.; Fox, J. L.; Biyashev, D.; Schelter, J. M.; Huang, Q.; Cleary, M. A.; Volpert, O. V.; Thomas-Tikhonenko, A. p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers. Cancer Res. 2011, 71, 7490-7501.
29. Carson, R. T.; Vignali, D. A. Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay. J. Immunol. Methods. 1999, 227, 41-52.
30. Dasso, J.; Lee, J.; Bach, H.; Mage, R. G. A comparison of ELISA and flow microsphere-based assays for quantification of immunoglobulins. J. Immunol. Methods. 2002, 263, 23-33.
31. Wolf, H.; zur Hausen, H.; Becker, V. EB viral genomes in epithelial nasopharyngeal carcinoma cells. Nat. New Biol. 1973, 244, 245-247.
32. Niedobitek, G. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Mol. Pathol. 2000, 53, 248-254.
33. Chelbi-Alix, M. K.; Wietzerbin, J. Interferon, a growing cytokine family: 50 years of interferon research. Biochimie 2007, 89, 713-718.
34. Chawla-Sarkar, M.; Leaman, D. W.; Jacobs, B. S.; Tuthill, R. J.; Chatterjee-Kishore, M.; Stark, G. R.; Borden, E. C. Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (Stat1). J. Interferon Cytokine Res. 2002, 22, 603-613.
35. Caraglia, M.; Abbruzzese, A.; Leardi, A.; Pepe, S.; Budillon, A.; Baldassare, G.; Selleri, C.; Lorenzo, S. D.; Fabbrocini, A.; Giuberti, G.; Vitale, G.; Lupoli, G.; Bianco, A. R.; Tagliaferri, P. Interferon-a induces apoptosis in human KB cells through a stressdependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor. Cell Death Differ. 1999, 6, 773-780.
36. Caraglia, M.; Tagliaferri, P.; Marra, M.; Giuberti, G.; Budillon, A.; Gennaro, E. D.; Pepe, S.; Vitale, G.; Improta, S.; Tassone, P.; Venuta, S.; Bianco, A. R.; Abbruzzese, A. EGF activates an inducible survival response via the RAS-> Erk-1/2 pathway to counteract interferon-alpha-mediated apoptosis in epidermoid cancer cells. Cell Death Differ. 2003, 10, 218-229.
37. Bruzzese, F.; Di Gennaro, E.; Avallone, A.; Pepe, S.; Arra, C.; Caraglia, M.; Tagliaferri, P.; Budillon, A. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo. Clin. Cancer Res. 2006, 12, 617-625.
38. Yang, J. L.; Qu, X. J.; Russell, P. J.; Goldstein, D. Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon alpha. Gut 2004, 53, 123-129.
39. Ruan, L.; Li, X. H.; Wan, X. X.; Yi, H.; Li, C.; Li, M. Y.; Zhang, P. F.; Zeng, G. Q.; Qu, J. Q.; He, Q. Y.; Li, J. H.; Chen, Y.; Chen, Z. C.; Xiao, Z. Q. Analysis of EGFR signaling pathway in nasopharyngeal carcinoma cells by quantitative phosphoproteomics. Proteome Sci. 2011, 9, 35.
40. Otrock, Z. K.; Mahfouz, R. A.; Makarem, J. A.; Shamseddine, A. I. Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells. Mol. Dis. 2007, 39, 212-220.
41. von Marschall, Z.; Scholz, A.; Cramer, T.; Schäfer, G.; Schirner, M.; Oberg, K.; Wiedenmann, B.; Höcker, M.; Rosewicz, S. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J. Natl. Cancer Inst. 2003, 95, 437-448.
42. Belardelli, F.; Gresser, I. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol. Today 1996, 17, 369-372.
43. Hervas-Stubbs, S.; Perez-Gracia, J. L.; Rouzaut, A.; Sanmamed, M. F.; Le, Bon. A.; Melero, I. Direct effects of type I interferons on cells of the immune system. Clin. Cancer Res. 2011, 17, 2619-2627.
44. Ferrantini, M.; Capone, I.; Belardelli, F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 2007, 89, 884-893.
45. Jinushi, M.; Tahara, H. Cytokine gene-mediated immunotherapy: current status and future perspectives. Cancer Sci. 2009, 100, 1389-1396.
46. Min, L.; Isa, S. A.; Fam, W. N.; Sze, S. K.; Beretta, O.; Mortellaro, A.; Ruedl, C. Synergism between curdlan and GM-CSF confers a strong inflammatory signature to dendritic cells. J. Immunol. 2012, 188, 1789-1798.
47. Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 2003, 3, 133-146.
48. Colombo, M. P.; Trinchieri, G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002, 13, 155-168.
49. Airoldi, I.; Ribatti, D. Regulation of angiostatic chemokines driven by IL-12 and IL-27 in human tumors. J. Leukoc. Biol. 2011, 90, 875-882.
50. Wills, R. J. Clinical pharmacokinetics of interferons. Clin. Pharmacokinet. 1990, 19, 390-399.